Disease relevance of Dipivefrine

• Large bulbar conjunctival follicles developed in 12 patients who received dipivefrin therapy for prolonged periods in the management of chronic open-angle glaucoma [1].
• The clinical course, the Giemsa staining of conjunctival scrapings, the conjunctival biopsy, and the results of patch tests suggest that this is an irritant reaction to dipivefrin rather than a reaction to preservatives or an allergic reaction [1].
• Seventy-six patients with open-angle glaucoma or ocular hypertension were randomly assigned to receive either betaxolol 0.5% or dipivefrin 0.1% [2].
• Contact dermatitis by dipivefrine [3].
• Follicular conjunctivitis on Dipivefrin therapy for glaucoma [4].

High impact information on Dipivefrine

• CONCLUSIONS: Apraclonidine, epinephrine, and dipivefrin eye drops inhibit PGE(2)-induced elevation of aqueous flare in pigmented rabbits [5].
• When timolol therapy was restored, the dipivefrin-treated group showed a more pronounced decrease of intraocular pressure (IOP) (8.2 +/- 1.5), whereas the IOP decrease in the nondipivefrin-treated group was lower (3.9 +/- 1.2) and of shorter duration (less than 60 days) [6].
• CONCLUSION: The observed data suggest that dipivefrin decreases ciliary body blood flow [7].
• Is it worthwhile to add dipivefrin HCl 0.1% to topical beta 1-, beta 2-blocker therapy [8]?
• Immunostaining with the use of antibodies to vimentin and actin revealed disorganization and condensation of cytoskeletal fibers in trabecular meshwork cells after treatment with epinephrine and dipivefrin [9].

Chemical compound and disease context of Dipivefrine

• The efficacy of the combination of l-moprolol and dipivefrin in reducing the intraocular pressure in primary open-angle glaucoma or in ocular hypertension [10].
• Levobunolol compared to dipivefrin in African American patients with open angle glaucoma [11].

Biological context of Dipivefrine

• CONCLUSIONS: In normals dipivefrin causes mydriasis but does not affect the central visual field global indices (as assessed by STATPAC), or high- and low-contrast LogMAR acuity [12].

Anatomical context of Dipivefrine

• To discuss the possible mechanisms of action and highlight the potential detrimental effects of dipivefrin on palpebral conjunctiva [13].
• In this study, the various antiglaucoma drugs including betaxolol, timolol, levobunolol, carteolol, brimonidine, dipivefrin, dorzolamide, brinzolamide, latanoprost, unoprostone, and pilocarpine were used to investigate the effects of cellular cytotoxicity in cultured bovine corneal endothelial cells [14].

Associations of Dipivefrine with other chemical compounds

• In a double-blind study design involving 33 young, healthy persons (mean age, 25 +/- 7 years), the effect of topically administered dipivefrin, naphazoline, and NaCl solution (0.9%) on the blood flow of iris and ciliary body was examined [7].
• This study supported the contention that dipivefrin is an effective and safe alternative to epinephrine therapy for the reduction of elevated intraocular pressure [15].
• In vitro studies showed that echothiophate is a competitive, reversible inhibitor of the soluble corneal dipivefrin esterases [16].
• BACKGROUND: In this double-blind prospective trial the efficacy of lowering the intraocular pressure of l-moprolol given alone and in combination with dipivefrin was tested [10].
• Intraocular pressure reductions were similar, with a mean decrease of 4.1 mm Hg in the betaxolol group and 3.5 mm Hg in the dipivefrin group [2].

Analytical, diagnostic and therapeutic context of Dipivefrine

• A significantly lower incidence of burning and stinging after drug instillation was noted with dipivefrin therapy [15].
• Treatment of the complication included the use of electrical stimulation, lymphatic drainage, antiinflammatory therapy, dipivefrine cloridrate drops, and other approaches [17].
• Relative to its less lipid soluble parent compound, dipivefrin has been shown in clinical trials to control intraocular pressure effectively at concentrations 10-20 times less than epinephrine with a resultant decreased incidence of ocular and systemic side effects [18].

References